<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet title='XSL_formatting' type='text/xsl' href='/rm_scripts/xsl/rss.xsl'?>
<rss version="2.0">
  <channel xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <title>Drug Abuse Screening - Research and Markets -  RSS Feed</title>
    <description>Drug Abuse Screening publications from researchandmarkets.com</description>
    <link>http://www.researchandmarkets.com</link>
    <language>en-US</language>
    <copyright>Copyright ResearchandMarkets.com 2009</copyright>
    <pubDate>Wed, 25 Nov 2009 00:19:34 GMT</pubDate>
    <lastBuildDate>Wed, 25 Nov 2009 00:19:34 GMT</lastBuildDate>
    <generator>Research And Markets</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <image>
      <title>Research And Markets</title>
      <url>http://www.researchandmarkets.com/rm_images/gif/rm_logo.gif</url>
      <link>http://www.researchandmarkets.com</link>
      <description>Research and Markets logo</description>
    </image>
    <skipHours />
    <item>
      <title>Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market</title>
      <description>Whilst narcolepsy is not a prevalent disorder, the recentsuccess of the first narcolepsy specific drug, Provigil(modafinil) has created interest in this previously neglectedmarket. With its superior efficacy and safety profilecompared to the previous gold</description>
      <link>http://www.researchandmarkets.com/reportinfo.asp?rfm=rss&amp;report_id=917</link>
      <author>press@researchandmarkets.com</author>
      <category>Drug Abuse Screening</category>
      <pubDate>Sat, 05 Oct 2002 12:19:00 GMT</pubDate>
      <guid isPermaLink="true">http://www.researchandmarkets.com/reportinfo.asp?rfm=rss&amp;report_id=917</guid>
    </item>
    <item>
      <title>Substance Abuse Disorders: A focus on the smoking cessation and alcohol addiction markets</title>
      <description>Substance abuse disorders are increasingly becoming a focus for companies active in niche psychiatric markets. The success of products such as Zyban has outlined the commercial potential in these disorders. Increasingly, manufacturers of established drug </description>
      <link>http://www.researchandmarkets.com/reportinfo.asp?rfm=rss&amp;report_id=1105</link>
      <author>press@researchandmarkets.com</author>
      <category>Drug Abuse Screening</category>
      <pubDate>Sat, 05 Oct 2002 12:19:00 GMT</pubDate>
      <guid isPermaLink="true">http://www.researchandmarkets.com/reportinfo.asp?rfm=rss&amp;report_id=1105</guid>
    </item>
  </channel>
</rss>